About My Health Careers Internship MedBlogs Contact us

Muscular Dystrophy Givinostat Drug can Help Treat Heart Failure

Font : A-A+

Muscular Dystrophy Givinostat Drug can Help Treat Heart Failure

  • Givinostat, new muscular dystrophy drug can help treat heart failure with preserved ejection fraction (HFpEF).
  • HFpEF occurs due to defective heart relaxation
  • After drug intake, cardiac relaxation without altering blood pressure was observed
Givinostat, a new drug used for muscular dystrophy can help the heart relax properly as in case of diastolic dysfunction (heart relaxation abnormality), the heart is unable to relax. If not treated this dysfunction can lead to heart failure. The findings of this study are published in the Journal of Science Translational Medicine.

Heart failure with preserved ejection fraction (HFpEF) refers to cases where the heart can pump blood normally but is not able to fill as efficiently as a healthy heart. Millions of people worldwide suffer from HFpEF, which can be caused by hypertension, diabetes, aging or other conditions. Individuals with HFpEF die at an alarming rate and, unfortunately, there are no effective drugs to treat this form of heart failure.


By studying of the hearts of patients with diastolic dysfunction and HFpEF, the research team found that fibrosis, the commonly suspected culprit in these cases, is not the sole cause of diastolic dysfunction. Instead, their findings indicated that there was a defect in the ability of the muscle cells of the heart to relax.

To address whether this defect in the muscle cells could be treated, the researchers, led by CU faculty members Mark Y. Jeong, MD, assistant professor of medicine, and Timothy A. McKinsey, Ph.D., associate professor of medicine, tested whether givinostat might improve the heart's ability to relax in the face of hypertension or aging.

They found that the investigational drug, tested in rat and mouse models, helped the heart relax properly. Thus, the findings hold promise for treating patients with diastolic dysfunction and HFpEF.

"These are exciting findings because we may be able to help patients with a form of heart failure that has been recalcitrant to standard-of-care therapies," said McKinsey. "Givinostat is currently in clinical development for the treatment of muscular dystrophy. Our data suggest the possibility that givinostat could be 'repurposed' for the treatment of HFpEF.

Obviously, it is early days, but we are excited to test givinostat in a large animal model of HFpEF as the next step toward translating our findings to humans. Our data also reveal relaxation impairment of muscle cells as a previously unrecognized process that contributes to diastolic dysfunction of the heart. Thus, other therapeutic strategies that improve this defect could also be useful for the treatment of HFpEF".

  1. Mark Y. Jeong, Ying H. Lin, Sara A. Wennersten,et.al. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism, Science Translational Medicine (2018).DOI: 10.1126/scitranslmed.aao0144

Source: Eurekalert

News A-Z
News Category
What's New on Medindia
January is the Thyroid Awareness Month in 2022
Menstrual Disorders
Coffee May Help You Fight Endometrial Cancer
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Muscular Dystrophy Congenital Heart Disease Signature Drug Toxicity Genetic Testing of Diseases Heart Healthy Heart Pulmonary Arterial Hypertension Statins Mitral Valve Prolapse 

Recommended Reading
Skeletal Muscle Developed for Duchenne Muscular Dystrophy
Skeletal muscle has been developed successfully from stem cells. This may offer stem cell ......
Master Muscle Marathon 2017: Run for Duchenne Muscular Dystrophy
Dystrophy Annihilation Trust, Bangalore (DART) conducted a special marathon to create awareness of ....
Breathing Capacity Can Be Restored in Duchenne Muscular Dystrophy
The respiratory system in patients with Duchenne muscular dystrophy (DMD) dysfunctions. The deficit ...
Salk Scientists Tweak CRISPR for Epigenetic Therapies in Diabetes, Kidney Disease and Muscular Dystrophy
A research team at the Salk Institute of Biological Studies, La Jolla has modified CRISPR/Cas9 ......
Congenital Heart Disease
Heart diseases that are present at birth are called “ Congenital heart diseases”....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Genetic Testing of Diseases
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laborat...
Mitral Valve Prolapse
Mitral Valve Prolapse is a relatively common condition and causes leakage of blood through the valve...
Muscular Dystrophy
Overview about muscular dystrophy, a muscle disease characterized by muscle weakness and muscle wast...
Pulmonary Arterial Hypertension
It can be a serious condition affecting the heart. It is defined as mean pulmonary arterial pressure...
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms bu...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)